Griffin Asset Management Inc. trimmed its holdings in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 14.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 257,679 shares of the company's stock after selling 42,641 shares during the period. Griffin Asset Management Inc. owned about 0.47% of Pulse Biosciences worth $2,883,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock valued at $7,379,000 after buying an additional 189,227 shares in the last quarter. Westside Investment Management Inc. raised its stake in shares of Pulse Biosciences by 97.8% during the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock valued at $712,000 after purchasing an additional 31,440 shares during the period. Inspire Investing LLC raised its stake in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after purchasing an additional 10,039 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of Pulse Biosciences during the fourth quarter valued at approximately $242,000. Finally, Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences during the first quarter valued at approximately $109,000. 76.95% of the stock is owned by institutional investors and hedge funds.
Pulse Biosciences Price Performance
Shares of NASDAQ:PLSE traded down $0.30 during midday trading on Thursday, reaching $21.53. The company had a trading volume of 118,724 shares, compared to its average volume of 216,425. The stock's fifty day moving average price is $15.00 and its 200-day moving average price is $11.24. The stock has a market capitalization of $1.32 billion, a P/E ratio of -26.58 and a beta of 1.75. Pulse Biosciences, Inc. has a one year low of $3.78 and a one year high of $22.21.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Tuesday, August 6th.
Read Our Latest Research Report on PLSE
About Pulse Biosciences
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
See Also
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
